RA
TEVA icon

Rockingstone Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Rockingstone Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.22M Buy
95,105
+1,955
+2% +$65.1K 1.29% 29
2026
Q1 		$2.81M Buy
93,150
+4,825
+5% +$155K 1.29% 37
2025
Q4 		$2.76M Buy
+88,325
New +$2.18M 1.26% 36

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return
FAF
Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Rockingstone Advisors's TEVA Position: Q2 2026 in Review

Rockingstone Advisors increased its Teva Pharmaceuticals (TEVA) stake by 2.1% in Q2 2026, buying an estimated $65.1K and bringing the position to 95,105 shares worth $3.22M. The position accounts for 1.29% of the portfolio, ranked #29.

Rockingstone Advisors first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 232 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Rockingstone Advisors held 95,105 shares of Teva Pharmaceuticals worth $3.22M as of Q2 2026.
  • Rockingstone Advisors bought 1,955 Teva Pharmaceuticals shares in Q2 2026, an estimated $65.1K.
  • Teva Pharmaceuticals made up 1.29% of Rockingstone Advisors's portfolio in Q2 2026, its #29 holding.
  • Rockingstone Advisors first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 232 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Rockingstone Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.